Thiazolidinone prodrugs activated by reactive oxygen species for use in the treatment of inflammatory diseases and cancer

Jorge Peiro Cadahia (Inventor), Mads Hartvig Clausen (Inventor), Jon Bondebjerg (Inventor), Christian Abildgaard Hansen (Inventor), Nikolaj Sten Andersen (Inventor)

Research output: Patent

121 Downloads (Pure)

Abstract

Prodrugs activated predominantly or exclusively in inflammatory tissue, more particularly prodrugs of methotrexate and derivatives thereof, which are selectively activated by Reactive Oxygen Species (ROS) in inflammatory tissues associated with cancer and inflammatory diseases, as well as method for preparing said prodrugs.
Original languageEnglish
IPCA61K31/519; A61P29/00; A61P35/00; C07D487/04
Patent numberWO2018037119
Filing date01/03/2018
CountryInternational Bureau of the World Intellectual Property Organization (WIPO)
Priority date26/08/2016
Priority numberEP20160185889
Publication statusPublished - 2018

Fingerprint Dive into the research topics of 'Thiazolidinone prodrugs activated by reactive oxygen species for use in the treatment of inflammatory diseases and cancer'. Together they form a unique fingerprint.

Cite this